Table 1 Baseline characteristics of patients in the propensity score–matched VEN/HMA and IC cohorts.
Variable | IC (n = 112) | VEN/HMA (n = 72) | P (IC vs VEN/HMA) |
|---|---|---|---|
Median age, years (range) | 48 (17–70) | 50 (15–70) | 0.154 |
Male sex, n (%) | 52 (46.6) | 34 (47.2) | 0.916 |
Hematological parameters | |||
 Median WBC, ×109/L (range) | 4.94 (0.46–381.61) | 3.6 (0.43–251) | 0.833 |
 Median Hb, g/L (range) | 77 (36–139) | 77 (50–113) | 0.237 |
 Median Plt, ×109/L (range) | 154 (4–1660) | 66 (8–587) | 0.002 |
 Median bone marrow blast (range), % | 67 (8–98) | 45 (8–94) | 0.233 |
Disease type, n (%) | |||
 De novo AML | 108 (96.4) | 69 (95.8) | 1.000 |
 S-AML/T-AML | 4 (3.6) | 3 (4.2) | 1.000 |
FAB classification | |||
 M0/1 | 15 (13.4) | 4 (5.6) | 0.088 |
 M5 | 32 (28.6) | 15 (20.8) | 0.240 |
Allo-HSCT, n (%) | 39 (34.8) | 11 (15.3) | 0.004 |
Gene fusion, n (%) | |||
 MLLT3::KMT2A | 0 (0) | 1 (1.4) | 0.391 |
 HOX11 | 1 (0.9) | 4 (5.6) | 0.078 |
Mutations, n (%) | |||
 FLT3 | 36 (32.1) | 23 (31.9) | 1.000 |
 FLT3-ITD | 29 (25.9) | 16 (22.2) | 0.603 |
 DNMT3A | 22 (19.6) | 20 (27.8) | 0.199 |
 TET2 | 10 (8.9) | 18 (25.0) | 0.004 |
 RAS | 20 (17.9) | 23 (31.9) | 0.033 |
 NRAS | 20 (17.9) | 15 (20.8) | 0.701 |
 KRAS | 3 (2.7) | 7 (9.7) | 0.050 |
 WT1 | 16 (14.3) | 11 (15.3) | 0.835 |
 KIT | 4 (3.6) | 2 (2.8) | 1.000 |
 GATA2 | 10 (8.9) | 7 (9.7) | 1.000 |
 PTPN11 | 9 (8.0) | 5 (6.9) | 1.000 |
 IDH | 26 (23.2) | 22 (30.6) | 0.268 |
 IDH1 | 7 (6.3) | 8 (11.1) | 0.276 |
 IDH2 | 13 (11.6) | 15 (20.8) | 0.097 |
 CSF3R | 4 (3.6) | 3 (4.2) | 0.563 |
 KMT2D | 3 (2.7) | 1 (1.4) | 1.000 |
